RPAM
Rhenman & Partners Asset Management Portfolio holdings
AUM
$791M
1-Year Return
12.81%
This Quarter Return
+7.19%
1 Year Return
+12.81%
3 Year Return
+98.32%
5 Year Return
+175.58%
10 Year Return
+579.5%
AUM
$811M
AUM Growth
+$71.2M
(+9.6%)
Cap. Flow
+$37.6M
Cap. Flow
% of AUM
4.63%
Top 10 Holdings %
Top 10 Hldgs %
28.89%
Holding
102
New
7
Increased
37
Reduced
34
Closed
10
Top Buys
| 1 |
Becton Dickinson
BDX
|
$16.3M |
| 2 |
CVS Health
CVS
|
$15.8M |
| 3 |
Bristol-Myers Squibb
BMY
|
$13.9M |
| 4 |
CELG
Celgene Corp
CELG
|
$12M |
| 5 |
Cigna
CI
|
$10.9M |
Top Sells
| 1 |
Nektar Therapeutics
NKTR
|
$15.5M |
| 2 |
ADMS
Adamas Pharmaceuticals, Inc.
ADMS
|
$11.5M |
| 3 |
Esperion Therapeutics
ESPR
|
$10.3M |
| 4 |
ITCI
Intra-Cellular Therapies Inc.
ITCI
|
$6.14M |
| 5 |
Cencora
COR
|
$6.03M |
Sector Composition
| 1 | Healthcare | 94.68% |
| 2 | Technology | 0.23% |
| 3 | Energy | 0.22% |
| 4 | Financials | 0.18% |
| 5 | Consumer Discretionary | 0.06% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
26
Elevance Health
ELV
$69.9B
| $13.4M | 1.65% |
61,000
+30,000
| +97% | +$6.59M |
|
27
Incyte
INCY
$16.7B
| $13.2M | 1.63% |
158,963
-4,740
| -3% | -$395K |
|
28
Abbott
ABT
$232B
| $12.1M | 1.49% |
202,000
+80,000
| +66% | +$4.79M |
|
29
Regeneron Pharmaceuticals
REGN
$60B
| $11.7M | 1.44% |
34,000
+2,846
| +9% | +$980K |
|
30
Edwards Lifesciences
EW
$47.5B
| $11.6M | 1.43% |
250,092
+30,000
| +14% | +$1.4M |
|
31
Biogen
BIIB
$20.3B
| $11.6M | 1.43% |
42,300
+27,000
| +176% | +$7.39M |
|
|
ARRY
32
DELISTED
Array Biopharma Inc
ARRY
| $11.4M | 1.41% |
701,470
+198,411
| +39% | +$3.24M |
|
|
ARNA
33
DELISTED
Arena Pharmaceuticals Inc
ARNA
| $11.3M | 1.39% |
285,642
-100,000
| -26% | -$3.95M |
|
|
AGN
34
DELISTED
Allergan plc
AGN
| $10.1M | 1.24% |
60,000
+948
| +2% | +$160K |
|
35
Alnylam Pharmaceuticals
ALNY
$59.5B
| $10M | 1.23% |
83,967
+25,000
| +42% | +$2.98M |
|
36
Boston Scientific
BSX
$160B
| $9.51M | 1.17% |
347,968
| – | – |
|
37
NovoCure
NVCR
$1.34B
| $9.48M | 1.17% |
435,000
-32,569
| -7% | -$710K |
|
38
Neurocrine Biosciences
NBIX
$13.7B
| $9.12M | 1.12% |
110,000
-7,969
| -7% | -$661K |
|
39
Xencor
XNCR
$602M
| $8.99M | 1.11% |
300,000
-17,500
| -6% | -$525K |
|
|
40
Cencora
COR
$56.8B
| $8.99M | 1.11% |
104,261
-70,000
| -40% | -$6.03M |
|
|
PTLA
41
DELISTED
Portola Pharmaceuticals, Inc.
PTLA
| $8.83M | 1.09% |
270,248
+59,095
| +28% | +$1.93M |
|
|
LOXO
42
DELISTED
Loxo Oncology, Inc
LOXO
| $8.65M | 1.07% |
75,000
-15,280
| -17% | -$1.76M |
|
|
MYOK
43
DELISTED
MyoKardia, Inc. Common Stock
MYOK
| $8.21M | 1.01% |
168,272
-10,000
| -6% | -$488K |
|
44
FibroGen
FGEN
$46M
| $7.83M | 0.97% |
6,782
| – | – |
|
45
Agios Pharmaceuticals
AGIO
$2.09B
| $7.77M | 0.96% |
95,000
-5,000
| -5% | -$409K |
|
46
MacroGenics
MGNX
$126M
| $7.55M | 0.93% |
300,000
-8,604
| -3% | -$216K |
|
47
Centene
CNC
$13.9B
| $6.95M | 0.86% |
130,000
+40,000
| +44% | +$2.14M |
|
|
SGEN
48
DELISTED
Seagen Inc. Common Stock
SGEN
| $6.8M | 0.84% |
+130,000
| New | +$6.8M |
|
|
RVNC
49
DELISTED
Revance Therapeutics, Inc.
RVNC
| $6.26M | 0.77% |
203,181
+20,601
| +11% | +$635K |
|
|
IMMU
50
DELISTED
Immunomedics Inc
IMMU
| $6.07M | 0.75% |
415,330
-65,000
| -14% | -$950K |
|